KR20200143718A - 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체 - Google Patents

이식편 거부반응 예방에 사용하기 위한 항-cd40 항체 Download PDF

Info

Publication number
KR20200143718A
KR20200143718A KR1020207032429A KR20207032429A KR20200143718A KR 20200143718 A KR20200143718 A KR 20200143718A KR 1020207032429 A KR1020207032429 A KR 1020207032429A KR 20207032429 A KR20207032429 A KR 20207032429A KR 20200143718 A KR20200143718 A KR 20200143718A
Authority
KR
South Korea
Prior art keywords
antibody
seq
dose
cfz533
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207032429A
Other languages
English (en)
Korean (ko)
Inventor
파스칼 에스피에
보에리에 하랄손
제임스 러쉬
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20200143718A publication Critical patent/KR20200143718A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207032429A 2018-04-13 2019-04-11 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체 Withdrawn KR20200143718A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
US62/657,172 2018-04-13
EP18208332 2018-11-26
EP18208332.9 2018-11-26
PCT/IB2019/052976 WO2019198019A1 (en) 2018-04-13 2019-04-11 Anti-cd40 antibodies for use in prevention of graft rejection

Publications (1)

Publication Number Publication Date
KR20200143718A true KR20200143718A (ko) 2020-12-24

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032429A Withdrawn KR20200143718A (ko) 2018-04-13 2019-04-11 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체

Country Status (13)

Country Link
US (2) US11780927B2 (enExample)
EP (1) EP3774913A1 (enExample)
JP (2) JP6861301B2 (enExample)
KR (1) KR20200143718A (enExample)
CN (1) CN111971307A (enExample)
AU (1) AU2019252858A1 (enExample)
BR (1) BR112020020277A2 (enExample)
CA (1) CA3094600A1 (enExample)
CL (1) CL2020002622A1 (enExample)
IL (1) IL277828A (enExample)
MX (1) MX2020010722A (enExample)
TW (1) TW201943731A (enExample)
WO (1) WO2019198019A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
JP2023548812A (ja) * 2020-10-26 2023-11-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫抑制剤の曲線下面積を評価する方法ならびに関連する方法及びシステム
CN118234749A (zh) * 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
KR20260116248A (ko) * 2023-11-28 2026-07-28 엘레던 파마슈티컬즈, 아이엔씨. 이식 거부반응 예방을 위한 방법 및 조성물
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
RU2006141632A (ru) * 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
IL277828A (en) 2020-11-30
US20240287198A1 (en) 2024-08-29
BR112020020277A2 (pt) 2021-01-19
CL2020002622A1 (es) 2021-04-16
JP6861301B2 (ja) 2021-04-21
EP3774913A1 (en) 2021-02-17
JP2021113190A (ja) 2021-08-05
MX2020010722A (es) 2020-11-06
US20210079107A1 (en) 2021-03-18
CN111971307A (zh) 2020-11-20
JP2020519634A (ja) 2020-07-02
TW201943731A (zh) 2019-11-16
AU2019252858A1 (en) 2020-10-08
WO2019198019A1 (en) 2019-10-17
US11780927B2 (en) 2023-10-10
CA3094600A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
CN102549015B (zh) 针对人血管生成素-2的高亲和力人抗体
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
WO2012059598A2 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
JP2013528608A (ja) ヒトｇｄｆ８に対する抗体
MX2013005477A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40.
KR20210114964A (ko) 화농성 한선염 치료에 사용하기 위한 항-cd40 항체
AU2022201425A1 (en) Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
US20230203176A1 (en) Methods For Prevention Of Graft Rejection In Xenotransplantation
KR20180039172A (ko) 루푸스 신염의 치료를 위한 항-cd40 항체의 용도
CN119768431A (zh) Igf1r抗体
RU2790558C2 (ru) Антитела к cd40 для применения в лечении синдрома шегрена
WO2025096432A1 (en) Treatment of anca-associated vasculitis
KR20260013511A (ko) 암 치료를 위한 조합 요법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202